The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the
diagnosis and treatment of adults with AML based on clinical trials that have led to …

Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …

RUNX1 is a critical transcription factor for the emergence of definitive hematopoiesis and the
precise regulation of adult hematopoiesis. Dysregulation of its regulatory network causes …

The frequency of pathogenic/likely pathogenic (P/LP) germ line variants in patients with
myelodysplastic syndrome (MDS) diagnosed at age 40 years or less is 15% to 20 …

Once thought to be exceedingly rare, the advent of next-generation sequencing has
revealed a plethora of germline predisposition disorders that confer risk for hematopoietic …

Deleterious germ line RUNX1 variants cause the autosomal dominant familial platelet
disorder with associated myeloid malignancy (FPDMM), characterized by thrombocytopenia …

Familial platelet disorder with associated myeloid malignancies (FPDMM) is caused by
germline RUNX1 mutations and characterized by thrombocytopenia and increased risk of …

Simple Summary Acute myeloid leukemia is a rare blood cancer that develops from the
clonal expansion of malignant myeloid precursor cells located in the bone marrow. Despite …

Erythropoiesis is a process of enormous magnitude, with the average person generating two
to three million red cells every second. Erythroid progenitors start as large cells with large …

Myeloid neoplasms with and without preexisting platelet disorders frequently develop in
association with an underlying germline predisposition. Germline alterations affecting …